This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arathoon, E. G.
Right arrow Articles by Sable, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arathoon, E. G.
Right arrow Articles by Sable, C. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2002, p. 451-457, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.451-457.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Eduardo G. Arathoon,1 Eduardo Gotuzzo,2 L. Miguel Noriega,3 Rayanne S. Berman,4 Mark J. DiNubile,4* and Carole A. Sable4

Hospital General San Juan de Dios, Guatemala City, Guatemala,1 Hospital Cayetano Heredia, Lima, Peru,2 Sotero del Rio Hospital, Santiago, Chile,3 Merck Research Laboratories, West Point, Pennsylvania4

Received 22 August 2001/ Returned for modification 13 October 2001/ Accepted 30 October 2001

Caspofungin is an antifungal agent of the novel echinocandin class. We investigated its efficacy, safety, and tolerability as therapy for oropharyngeal and/or esophageal candidiasis in a phase II dose-ranging study. Patients were randomized in a double-blind manner to receive either caspofungin acetate (35, 50, or 70 mg) or amphotericin B (0.5 mg/kg of body weight) intravenously once daily for 7 to 14 days. A favorable response required both complete resolution of symptoms and quantifiable improvement of mucosal lesions 3 to 4 days after discontinuation of study drug. Efficacy was assessed using a modified intent-to-treat analysis. No hypothesis testing of efficacy was planned or performed. Of 140 enrolled patients, 63% had esophageal involvement and 98% were infected with the human immunodeficiency virus (HIV) (median CD4 count, 30/mm3). A modestly higher proportion of patients in each of the caspofungin groups (74 to 91%) achieved favorable responses compared to amphotericin B recipients (63%), but there was considerable overlap in the 95% confidence intervals surrounding these point estimates. Similar trends were found in the subgroups with esophageal involvement, a history of fluconazole failure, and CD4 counts of <=50/mm3. A smaller proportion of patients receiving any dose of caspofungin experienced drug-related adverse events compared to patients given standard doses of conventional amphotericin B (P < 0.01). Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study.

* Corresponding author. Mailing address: Clinical Research Publications (Infectious Diseases), Merck Research Laboratories, P.O. Box 4, BL3-4, West Point, PA 19486. Phone: (484) 344-3331. Fax: (484) 344-3404. E-mail: mark_dinubile{at}merck.com.

Antimicrobial Agents and Chemotherapy, February 2002, p. 451-457, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.451-457.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sucher, A. J, Chahine, E. B, Balcer, H. E (2009). Echinocandins: The Newest Class of Antifungals. The Annals of Pharmacotherapy 43: 1647-1657 [Abstract] [Full Text]  
  • Neely, M., Jafri, H. S., Seibel, N., Knapp, K., Adamson, P. C., Bradshaw, S. K., Strohmaier, K. M., Sun, P., Bi, S., Dockendorf, M. F., Stone, J. A., Kartsonis, N. A. (2009). Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers. Antimicrob. Agents Chemother. 53: 1450-1456 [Abstract] [Full Text]  
  • Saez-Llorens, X., Macias, M., Maiya, P., Pineros, J., Jafri, H. S., Chatterjee, A., Ruiz, G., Raghavan, J., Bradshaw, S. K., Kartsonis, N. A., Sun, P., Strohmaier, K. M., Fallon, M., Bi, S., Stone, J. A., Chow, J. W. (2009). Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age. Antimicrob. Agents Chemother. 53: 869-875 [Abstract] [Full Text]  
  • Zaoutis, T. E., Jafri, H. S., Huang, L.-M., Locatelli, F., Barzilai, A., Ebell, W., Steinbach, W. J., Bradley, J., Lieberman, J. M., Hsiao, C.-C., Seibel, N., Laws, H.-J., Gamba, M., Petrecz, M., Taylor, A. F., Strohmaier, K. M., Chow, J. W., Kartsonis, N. A., Ngai, A. L. (2009). A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients. Pediatrics 123: 877-884 [Abstract] [Full Text]  
  • Lionakis, M. S., Samonis, G., Kontoyiannis, D. P. (2008). Endocrine and Metabolic Manifestations of Invasive Fungal Infections and Systemic Antifungal Treatment. Mayo Clin Proc. 83: 1046-1060 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J., Walsh, T. J. (2008). Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. J. Clin. Microbiol. 46: 2620-2629 [Abstract] [Full Text]  
  • Mistry, G. C., Migoya, E., Deutsch, P. J., Winchell, G., Hesney, M., Li, S., Bi, S., Dilzer, S., Lasseter, K. C., Stone, J. A. (2007). Single- and Multiple-Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations. J Clin Pharmacol 47: 951-961 [Abstract] [Full Text]  
  • Nguyen, T. H., Hoppe-Tichy, T., Geiss, H. K., Rastall, A. C., Swoboda, S., Schmidt, J., Weigand, M. A. (2007). Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 60: 100-106 [Abstract] [Full Text]  
  • Veroux, M., Corona, D., Macarone, M., Gagliano, M., Giuffida, G., Veroux, P. (2007). Caspofungin in kidney transplant recipients with refractory invasive candidiasis. Nephrol Dial Transplant 22: 1487-1488 [Full Text]  
  • Blyth, C. C., Palasanthiran, P., O'Brien, T. A. (2007). Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review. Pediatrics 119: 772-784 [Abstract] [Full Text]  
  • Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 1.. Am J Health Syst Pharm 63: 1693-1703 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2006). In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance.. J. Clin. Microbiol. 44: 760-763 [Abstract] [Full Text]  
  • Duffalo, M. L. (2006). Fungal Opportunistic Infections in HIV Disease. Journal of Pharmacy Practice 19: 17-30 [Abstract]  
  • Louie, A., Deziel, M., Liu, W., Drusano, M. F., Gumbo, T., Drusano, G. L. (2005). Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity. Antimicrob. Agents Chemother. 49: 5058-5068 [Abstract] [Full Text]  
  • Walsh, T. J., Adamson, P. C., Seibel, N. L., Flynn, P. M., Neely, M. N., Schwartz, C., Shad, A., Kaplan, S. L., Roden, M. M., Stone, J. A., Miller, A., Bradshaw, S. K., Li, S. X., Sable, C. A., Kartsonis, N. A. (2005). Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents. Antimicrob. Agents Chemother. 49: 4536-4545 [Abstract] [Full Text]  
  • Wegner, B., Baer, P., Gauer, S., Oremek, G., Hauser, I. A., Geiger, H. (2005). Caspofungin is less nephrotoxic than amphotericin B in vitro and predominantly damages distal renal tubular cells. Nephrol Dial Transplant 20: 2071-2079 [Abstract] [Full Text]  
  • Kartsonis, N., Killar, J., Mixson, L., Hoe, C.-M., Sable, C., Bartizal, K., Motyl, M. (2005). Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome. Antimicrob. Agents Chemother. 49: 3616-3623 [Abstract] [Full Text]  
  • Sandhu, P., Lee, W., Xu, X., Leake, B. F., Yamazaki, M., Stone, J. A., Lin, J. H., Pearson, P. G., Kim, R. B. (2005). HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN. Drug Metab. Dispos. 33: 676-682 [Abstract] [Full Text]  
  • Goldblum, D., Frueh, B. E., Sarra, G.-M., Katsoulis, K., Zimmerli, S. (2005). Topical Caspofungin for Treatment of Keratitis Caused by Candida albicans in a Rabbit Model. Antimicrob. Agents Chemother. 49: 1359-1363 [Abstract] [Full Text]  
  • Moudgal, V., Little, T., Boikov, D., Vazquez, J. A. (2005). Multiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis. Antimicrob. Agents Chemother. 49: 767-769 [Abstract] [Full Text]  
  • Stone, J. A., Migoya, E. M., Hickey, L., Winchell, G. A., Deutsch, P. J., Ghosh, K., Freeman, A., Bi, S., Desai, R., Dilzer, S. C., Lasseter, K. C., Kraft, W. K., Greenberg, H., Waldman, S. A. (2004). Potential for Interactions between Caspofungin and Nelfinavir or Rifampin. Antimicrob. Agents Chemother. 48: 4306-4314 [Abstract] [Full Text]  
  • Petraitis, V., Petraitiene, R., Kelaher, A. M., Sarafandi, A. A., Sein, T., Mickiene, D., Bacher, J., Groll, A. H., Walsh, T. J. (2004). Efficacy of PLD-118, a Novel Inhibitor of Candida Isoleucyl-tRNA Synthetase, against Experimental Oropharyngeal and Esophageal Candidiasis Caused by Fluconazole-Resistant C. albicans. Antimicrob. Agents Chemother. 48: 3959-3967 [Abstract] [Full Text]  
  • Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszynska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., dePauw, B. E. (2004). Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia. NEJM 351: 1391-1402 [Abstract] [Full Text]  
  • Kartsonis, N. A., Saah, A., Lipka, C. J., Taylor, A., Sable, C. A. (2004). Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J Antimicrob Chemother 53: 878-881 [Abstract] [Full Text]  
  • Sandhu, P., Xu, X., Bondiskey, P. J., Balani, S. K., Morris, M. L., Tang, Y. S., Miller, A. R., Pearson, P. G. (2004). Disposition of Caspofungin, a Novel Antifungal Agent, in Mice, Rats, Rabbits, and Monkeys. Antimicrob. Agents Chemother. 48: 1272-1280 [Abstract] [Full Text]  
  • Hernandez, S., Lopez-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., Graybill, J. R. (2004). Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis. Antimicrob. Agents Chemother. 48: 1382-1383 [Abstract] [Full Text]  
  • Stone, J. A., Xu, X., Winchell, G. A., Deutsch, P. J., Pearson, P. G., Migoya, E. M., Mistry, G. C., Xi, L., Miller, A., Sandhu, P., Singh, R., deLuna, F., Dilzer, S. C., Lasseter, K. C. (2004). Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma. Antimicrob. Agents Chemother. 48: 815-823 [Abstract] [Full Text]  
  • Letscher-Bru, V., Herbrecht, R. (2003). Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 51: 513-521 [Abstract] [Full Text]  
  • Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., Perfect, J., the Caspofungin Invasive Candidiasis Study Group, (2002). Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis. NEJM 347: 2020-2029 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2002). Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility. J. Clin. Microbiol. 40: 3551-3557 [Full Text]  
  • (2002). Caspofungin vs. Amphotericin B for Oropharyngeal and Esophageal Candidiases. JWatch Infect. Diseases 2002: 5-5 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»